Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Journal of Andrology
|
September 11, 1998
Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum
L S Grauer, J A Finlay, S D Mikolajczyk, et al.
The Prostate
|
January 1, 1996
Dual monoclonal antibody immunoassay for free prostate-specific antigen
T J Wang, T M Hill, R L Sokoloff, et al.
Cancer Research
|
November 11, 1998
Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line
L S Grauer, K D Lawler, J L Marignac, et al.
Journal of Immunological Methods
|
June 24, 1994
Enhanced immunogenicity of leucine enkephalin following coupling to anti-immunoglobulin and anti-CD3 antibodies
T L Hendrickson, G S Wilson, J M Frazer, et al.
Urology
|
October 24, 1997
Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay
W J Ellis, R L Vessella, J L Noteboom, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
January 11, 2000
Western blotting analysis of antibodies to prostate-specific antigen: specificities for prostate-specific antigen and prostate-specific antigen fragments
T J Wang, H J Linton, R L Sokoloff, et al.
JAMA
|
October 18, 1995
Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
W J Catalona, D S Smith, R L Wolfert, et al.
Urology
|
August 12, 1999
Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model
W J Catalona, A W Partin, J A Finlay, et al.
British Journal of Cancer
|
September 4, 2008
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel
K Oikonomopoulou, L Li, Y Zheng, et al.
Clinical Chemistry
|
October 7, 1998
The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia
M S Saedi, T M Hill, K Kuus-Reichel, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Journal of Andrology
|
September 11, 1998
Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum
L S Grauer, J A Finlay, S D Mikolajczyk, et al.
The Prostate
|
January 1, 1996
Dual monoclonal antibody immunoassay for free prostate-specific antigen
T J Wang, T M Hill, R L Sokoloff, et al.
Cancer Research
|
November 11, 1998
Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line
L S Grauer, K D Lawler, J L Marignac, et al.
Journal of Immunological Methods
|
June 24, 1994
Enhanced immunogenicity of leucine enkephalin following coupling to anti-immunoglobulin and anti-CD3 antibodies
T L Hendrickson, G S Wilson, J M Frazer, et al.
Urology
|
October 24, 1997
Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay
W J Ellis, R L Vessella, J L Noteboom, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
January 11, 2000
Western blotting analysis of antibodies to prostate-specific antigen: specificities for prostate-specific antigen and prostate-specific antigen fragments
T J Wang, H J Linton, R L Sokoloff, et al.
JAMA
|
October 18, 1995
Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
W J Catalona, D S Smith, R L Wolfert, et al.
Urology
|
August 12, 1999
Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model
W J Catalona, A W Partin, J A Finlay, et al.
British Journal of Cancer
|
September 4, 2008
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel
K Oikonomopoulou, L Li, Y Zheng, et al.
Clinical Chemistry
|
October 7, 1998
The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia
M S Saedi, T M Hill, K Kuus-Reichel, et al.
Page
of 4